You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ERBB2

Showing 1 - 25 of 424
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Cancer, HER2 Gene Mutation Trial in Seoul (Neratinib Maleate)

Active, not recruiting
  • Metastatic Cancer
  • HER2 Gene Mutation
  • Neratinib Maleate
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Oct 18, 2023

Breast Tumors Trial in Saint Louis (Doxorubicin, Trastuzumab, Cyclophosphamide)

Terminated
Has Results
  • Breast Neoplasms
  • Saint Louis, Missouri
    Washington University School of Medicine
Oct 31, 2022

Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma Trial in Scottsdale,

Not yet recruiting
  • Metastatic Colon Adenocarcinoma
  • +5 more
  • Trastuzumab
  • +2 more
  • Scottsdale, Arizona
  • +2 more
Jan 31, 2023

Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial

Recruiting
  • Metastatic Salivary Gland Carcinoma
  • +4 more
  • New York, New York
    Memorial Sloane Kettering Cancer Center
Jan 11, 2023

HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,

Completed
Has Results
  • HER2 Positive Breast Carcinoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Sep 22, 2022

Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +4 more
  • Necitumumab
  • +4 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Jan 5, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Tumor in the Brain Trial in Duarte

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Copper Cu 64-DOTA-Trastuzumab
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Nov 22, 2022

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

Tumors, Breast Trial in France, Ireland, United States (lapatinib, docetaxel, trastuzumab)

Terminated
  • Neoplasms, Breast
  • lapatinib, docetaxel, trastuzumab
  • Nashville, Tennessee
  • +4 more
Jun 30, 2022

Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48 Trial in Guanzhou (RC48+Tislelizumab+carboplatin,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • Guanzhou, China
    SunYat-senU
May 5, 2023

Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in Bellevue, Grand Island, Omaha (drug, other,

Active, not recruiting
  • Estrogen Receptor Negative
  • +15 more
  • Bellevue, Nebraska
  • +3 more
Nov 30, 2022

Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Los Angeles, California
  • +4 more
Jul 19, 2022

EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

Recruiting
  • EGFR Exon 20 Mutation
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 12, 2022

Breast Tumor, Breast Carcinoma, Receptor, ErbB-2 Trial in Brussels (68GaNOTA-Anti-HER2 VHH1)

Recruiting
  • Breast Neoplasm
  • +2 more
  • 68GaNOTA-Anti-HER2 VHH1
  • Brussels, Belgium
    Uz Brussel
Mar 4, 2022

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8

Recruiting
  • Anatomic Stage II Breast Cancer AJCC v8
  • +19 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
May 11, 2022

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial

Recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +19 more
  • pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 1, 2022

Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7 Trial in United States

Recruiting
  • Breast Adenocarcinoma
  • +7 more
  • Multi-epitope HER2 Peptide Vaccine TPIV100
  • +5 more
  • Scottsdale, Arizona
  • +26 more
Aug 17, 2022

HER2 Positive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 Trial in Norfolk, Omaha (drug,

Active, not recruiting
  • HER2 Positive Breast Carcinoma
  • +6 more
  • Norfolk, Nebraska
  • +2 more
Sep 1, 2021

Receptor, ErbB-2 Trial (SSGJ-705)

Not yet recruiting
  • Receptor, ErbB-2
  • (no location specified)
Nov 25, 2021

HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer Trial in Duarte (radiation, other,

Active, not recruiting
  • HER2 Positive Breast Carcinoma
  • +3 more
  • Copper Cu 64-DOTA-Trastuzumab
  • +5 more
  • Duarte, California
    City of Hope Medical Center
May 17, 2021

Metastatic Breast Cancer Trial in Durham (dHER2 + AS15 ASCI, Lapatinib)

Completed
Has Results
  • Metastatic Breast Cancer
  • Durham, North Carolina
    Duke University Medical Center
Nov 18, 2021

Breast Cancer Trial in Portugal, Spain (Neratinib + endocrine therapy)

Recruiting
  • Breast Cancer
  • Neratinib + endocrine therapy
  • Lisboa, Portugal
  • +14 more
Jul 23, 2021

Tumors, Breast Trial in United States (lapatinib, bevacizumab)

Completed
Has Results
  • Neoplasms, Breast
  • Tucson, Arizona
  • +8 more
Sep 28, 2021

Solid Tumor Trial in Worldwide (BDTX-189)

Terminated
  • Solid Tumor
  • Scottsdale, Arizona
  • +37 more
Oct 13, 2022

Advanced Malignant Solid Tumor, Estrogen Receptor Positive, HER2/Neu Positive Trial in United States (drug, other, biological)

Completed
  • Advanced Malignant Solid Neoplasm
  • +12 more
  • Houston, Texas
  • +4 more
Dec 16, 2020